ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT ARS PHARMACEUTICALS, INC.

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY)
Listen to this Section


$8.60
-0.4720 ( -5.20% ) 526.1K

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.

Market Data


Open $8.60
Previous Close $9.07
Volume 526.1K
Market Cap $868.90M
Day Range $8.42 - $9.08
52 Week Range $6.66 - $18.90
Shares Outstanding 99.30M
Change % -5.20%
Net Change ▼ -0.4720
Insider Ownership -0.24%
Exchange NASDAQ
SectorMiscellaneous
IndustryNone
IPO Year2022
CountryUnited States
UnderwriterIPO Intelligence Only

Insider Ownership Transactions

Total Amount Purchased: -1,273,987.00

Date Type Amount Purchased Purchaser
2024-06-24 Sale -40000.00 Islam Saqib
2024-06-24 Sale -40000.00 Thompson Peter A.
2024-06-24 Sale -40000.00 Dadoo Rajeev
2024-06-17 Sale -200000.00 Shah Pratik
2024-06-13 Sale -2166.00 Lowenthal Richard E
2024-06-13 Sale -2166.00 Tanimoto Sarina
2024-06-07 Sale -1332950.00 Shah Pratik
2024-06-06 Sale -2665800.00 Shah Pratik
2024-05-16 Sale -2873.00 Lowenthal Richard E
2024-05-16 Sale -2873.00 Tanimoto Sarina

SEC Filings


Form Type Description Pages Date
10-q Quarterly Reports 83 Nov 10, 2025
8-k 8K-related 33 Nov 10, 2025
8-k 8K-related 13 Sep 29, 2025
8-k 8K-related 12 Aug 28, 2025
4 Insider transactions 1 Aug 22, 2025
4 Insider transactions 1 Aug 22, 2025
4 Insider transactions 1 Aug 21, 2025
10-q Quarterly Reports 81 Aug 13, 2025
8-k 8K-related 32 Aug 13, 2025
4 Insider transactions 1 Jul 03, 2025

Latest News


× Before browsing our site, please accept our cookies policy